期刊文献+

持续静脉滴注氟尿嘧啶联合顺铂治疗晚期头颈部癌 被引量:17

Analysis of chemotherapy with 5-FU by continous intravenous infusion and cisplatin in head and neck advanced cancer
下载PDF
导出
摘要 背景与目的:顺铂与氟尿嘧啶是治疗晚期头颈部肿瘤疗效确切的药物,但有一定的毒性反应。本研究观察持续静脉滴注氟尿嘧啶联合顺铂治疗晚期头颈部癌的疗效及安全性。方法:22例晚期头颈部癌患者给予氟尿嘧啶750mg/(m2.d)持续静脉滴注5d(120h),顺铂25mg/(m2.d),d1~3。21d为一个周期,2个周期后评价疗效。结果:CR1例(4.5%),PR8例(36.4%),近期客观有效率为40.9%(9/22)。中位TTP7.4个月,1年生存率为72.7%。初治与复治有效率分别为75.0%(6/8),21.4%(3/14),统计学差异有显著性(χ2=6.04,P<0.05)。主要毒副反应为骨髓抑制、胃肠道反应和粘膜炎。结论:持续静脉滴注氟尿嘧啶联合顺铂治疗晚期头颈部癌具有较好的疗效,安全性好。 Background and purpose:Cisplatin and 5-fluorouracil (5-FU) have demonstrated significant activity in patients with advanced head and neck cancer despite relevant toxicity. We evaluated the efficacy and toxicity of combination chemotherapy using continuous intravenous infusion 5-FU plus cisplatin for locally advanced, recurrent, or metastatic head and neck cancer patients. Methods:twenty-two patients with locally advanced, recurrent, or metastatic head and neck cancer were treated by cisplatin 25 mg/(m2·d) day 1-3 and fluorouracil 750 mg/(m2·d) 120 hours by continuous intravenous infusion day 1 through 5 every 21 days as one cycle.Results:Of 22 assessable patients, 1 (4.5%)showed completed response and 8 partial response with an overall response rate of 40.9%(9/22). Median time to progression was 7.7 months, and 1-year survival was 72.2%. The toxicity mainly included grade 1/2 myleosuppression, reaction of stomach intestinal, mucositis. Response rate of initial treatment and retreatment were 75.0%(6/8),21.4%(3/14), respectively (χ2=6.04,P〈0.05).Conclusions:chemotherapy with 5-FU by continous intravenous infusion and cisplatin is safe and effective for patients with locally advanced, recurrent, or metastatic head and neck cancer.
出处 《中国癌症杂志》 CAS CSCD 2007年第9期716-718,共3页 China Oncology
关键词 头颈部肿瘤 氟尿嘧啶 顺铂 晚期 化学治疗 head and neck neoplasm fluorouracil cisplatin advanced chemotherapy
  • 相关文献

参考文献7

  • 1Jacobs C,Lyman G,Velez-Garcia E,et al.A phase Ⅲ randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck[J].J Clin Oncol,1992,10(2):257-263. 被引量:1
  • 2Forastiere AA,Metch B,Schulter DE,et al.Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck:a Southwest Oncology Group study[J].J Clin Oncol,1992,10(8):1245-1251. 被引量:1
  • 3王佳蕾,洪小南,唐惟瑜,郭晔,李进.吉西他滨联合顺铂治疗头颈部癌52例分析[J].中华肿瘤杂志,2005,27(9):567-569. 被引量:9
  • 4Gibson MK,Li Y,Murphy B,et al.Randomized phase Ⅲ evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395):an intergroup trial of the Eastern Cooperative Oncology Group[J].J Clin Oncol,2005,23(15):3562-3567. 被引量:1
  • 5陈怀宇,王晓怀,侯友贤,谢波,戴辉,王者非,李荔霞,林金容.含紫杉醇化疗方案治疗晚期头颈部恶性肿瘤[J].中国癌症杂志,2001,11(4):319-321. 被引量:9
  • 6Benasso M,Ponzanelli A,Medano M,et al.Paclitaxel,cisplatin and 5-fluorouracil in recurrent squamous cell carcinoma of the head and neck:a phase Ⅱ trial from an Italian cooperative group[J].Acta Oncol,2006,45(2):168-174. 被引量:1
  • 7Schena M,Barone C,Birocco N,et al.Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma:a phase Ⅱ study[J].Cancer Chemother Pharmacol,2005,55(3):271-276. 被引量:1

二级参考文献8

  • 1Lee AW, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985:overall survival and patterns of failure. Int J Radiat Oncol Biol Phys, 1992, 23:261-270. 被引量:1
  • 2Khuri FR, Shin DM, Glisson BS, et al. Treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck: current status and future directions. Semin Oncol, 2000, 27: 25-33. 被引量:1
  • 3Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck:a southeast oncology group study. J Clin Oncol, 1992, 10: 1245-1251. 被引量:1
  • 4Hitt R, Castellano D, Hidalgo M, et al. Phase II trial of cisplatin and gemcitabine in advanced squamous-cell carcinoma of the head and neck. Ann Oncol, 1998, 9:1347-1349. 被引量:1
  • 5Foo K, Tan EH, Leong SS, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type. Ann Oncol, 2002, 13:150-156. 被引量:1
  • 6Ngan RK, Yiu HH, Lau WH, et al. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma:report of a phase II study. Ann Oncol, 2002,13:1252-1258. 被引量:1
  • 7Ma BBY, Tannock IF, Pond GR, et al. Chemotherapy with gemcitabine-containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma. Cancer, 2002, 95:2516-2523. 被引量:1
  • 8何侠,洪明晃,何友兼,闵华庆.鼻咽癌远处转移化疗新方案近期疗效及治疗策略初探[J].癌症,1999,18(3):300-302. 被引量:28

共引文献16

同被引文献102

引证文献17

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部